R&D Pipeline

Events

Sentinel Oncology will be participating in the following events

 

 

 

 

 

Contact

For further details and to arrange a discussion about licensing a Sentinel Oncolgy programme, please click the link above or contact 

+44(0)1223 437123

busdev@sentineloncology.com

Sentinel Oncology Pipeline

pipeline_1111_550

Checkpoint Kinase 1 (Chk1)

DNA damage occurs frequently with as many as 10,000 errors introduced into every cell each day.  The DNA damage response (DDR) is a fundamental process required to ensure the integrity of genomic information.  The protein kinase Chk1 performs a crucial role in sensing and responding to DNA damage. Sentinel Oncology is developing potent, selective and oral inhibitors for use as single agents and in combination with chemotherapy..... read more

 

p70S6 Kinase (p70S6K)

Phosphoinositide 3-kinase (PI3K) signalling plays a pivotal role in cancer and the development of inhibitors targeting the pathway has received significant R&D efforts. Temsirolimus, an inhibitor of mTORC1 has now been approved by the FDA for the treatment of advanced renal cell carcinoma. The enzyme, p70S6 kinase (p70S6K) is a serine-threonine kinase and a key component of the PI3K-mTOR pathway which is vital for the growth and survival of cancer cells..... read more

 

Targeted Synergy (TS)

Cancers arising in solid tissues will affect roughly one in every four individuals worldwide, making them a major health problem that offers extensive commercial opportunities. Sentinel Oncology is developing a new approach for the treatment of cancer, “Targeted Synergy” in which a single drug delivers two synergistic activities, DNA damage and inhibition of DNA repair, to the areas of low oxygenation (hypoxic regions) found in most solid tumours.... read more